Developing a drug is a long and expensive process and can be a brake to innovation. Guillaume Leboucher has co-founded Labtoo, an accelerator of R&D, in order to link more efficiently all R&D stakeholders.
The COVID-19 has strongly impacted the biotech ecosystem as evidenced by a recent survey conducted by Labtoo. Our platform has rapidly evolved with this sanitary crisis, by referencing many research projects on COVID-19 and who amÂong the research community was able to work on those projects.
This platform dedicated to the coronavirus issue is still operating to this day, and Labtoo has supported a dozen of research projects against the COVID-19 so far.